Moderna

Moderna, founded in 2010, is a pioneering force in mRNA medicine, specializing in the rapid development of vaccines and therapeutics for infectious diseases, cancer, rare disorders, and autoimmune conditions. By leveraging a proprietary technology platform, the company has fundamentally reshaped how treatments are discovered, manufactured, and delivered to patients globally. This innovative approach allows for accelerated clinical development cycles, positioning the firm as a critical entity within the biopharmaceutical sector. Learn about Moderna's global headquarters for comprehensive details on their primary operational footprint located in Cambridge, Massachusetts.

Currently operating with 1,000-5,000 employees, Moderna maintains a highly specialized workforce distributed across three strategic locations. The company’s internal culture emphasizes scientific rigor and collaborative problem-solving, which is essential for managing complex drug development programs. Their organizational structure is designed to support end-to-end manufacturing services and clinical-stage biotechnology initiatives. Meet Moderna's team to gain deeper insights into the leadership, scientific expertise, and operational management teams that drive their ongoing research and development efforts in the life sciences field.

Traded under the ticker NASDAQ: MRNA, Moderna has established a significant market presence, reporting annual revenue of $2.2B. The company’s financial trajectory is supported by a history of strategic funding, including grants from the Bill & Melinda Gates Foundation and BARDA, alongside various stock offerings. Explore financial highlights to review their detailed fiscal performance, capital structure, and long-term investment outlook within the highly competitive landscape of global drug discovery and pharmaceutical manufacturing.